{"componentChunkName":"component---node-modules-narative-gatsby-theme-novela-src-templates-article-template-tsx","path":"/gland-pharma-a-long-unwinding-ahead","result":{"pageContext":{"article":{"id":"919bdb98-fc2d-5224-9df8-4eb6f16cec3b","slug":"/gland-pharma-a-long-unwinding-ahead","secret":false,"title":"Gland Pharma - A Long Unwinding Ahead","author":"Abhishek Jain","date":"March 25th, 2021","dateForSEO":"2021-03-25T00:00:00.000Z","timeToRead":5,"excerpt":"Writing My First Ever blog","canonical_url":null,"subscription":true,"body":"function _extends() { _extends = Object.assign || function (target) { for (var i = 1; i < arguments.length; i++) { var source = arguments[i]; for (var key in source) { if (Object.prototype.hasOwnProperty.call(source, key)) { target[key] = source[key]; } } } return target; }; return _extends.apply(this, arguments); }\n\nfunction _objectWithoutProperties(source, excluded) { if (source == null) return {}; var target = _objectWithoutPropertiesLoose(source, excluded); var key, i; if (Object.getOwnPropertySymbols) { var sourceSymbolKeys = Object.getOwnPropertySymbols(source); for (i = 0; i < sourceSymbolKeys.length; i++) { key = sourceSymbolKeys[i]; if (excluded.indexOf(key) >= 0) continue; if (!Object.prototype.propertyIsEnumerable.call(source, key)) continue; target[key] = source[key]; } } return target; }\n\nfunction _objectWithoutPropertiesLoose(source, excluded) { if (source == null) return {}; var target = {}; var sourceKeys = Object.keys(source); var key, i; for (i = 0; i < sourceKeys.length; i++) { key = sourceKeys[i]; if (excluded.indexOf(key) >= 0) continue; target[key] = source[key]; } return target; }\n\n/* @jsxRuntime classic */\n\n/* @jsx mdx */\nvar _frontmatter = {\n  \"title\": \"Gland Pharma - A Long Unwinding Ahead\",\n  \"author\": \"Abhishek Jain\",\n  \"date\": \"2021-03-25T00:00:00.000Z\",\n  \"hero\": \"./images/hero.jpg\",\n  \"excerpt\": \"Writing My First Ever blog\"\n};\nvar layoutProps = {\n  _frontmatter: _frontmatter\n};\nvar MDXLayout = \"wrapper\";\nreturn function MDXContent(_ref) {\n  var components = _ref.components,\n      props = _objectWithoutProperties(_ref, [\"components\"]);\n\n  return mdx(MDXLayout, _extends({}, layoutProps, props, {\n    components: components,\n    mdxType: \"MDXLayout\"\n  }), mdx(\"p\", null, \"Well-positioned to Capitalise Fast-growing \", mdx(\"strong\", {\n    parentName: \"p\"\n  }, \"Generic Injectibles\"), \" Market\\nIn the US, Injectables Market is expected to grow at \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"15.3% CAGR\"), \" primarily due to doubling\\nof the value (~USD$ 67.7 bn) of molecules losing exclusivity over 2020-2025E. Gland Pharma\\nhas developed complex injectables such as lyophilized products, high-potent drugs, and long-\\nacting suspensions having 282 ANDA filings in the United States, of which 226 were approved\\nand 56 pending approval. The manufacturing facilities\\u2019 audit is conducted by Marketer companies\\npartners ensures its compliance with the regulatory requirements all the time. This has resulted\\ninto zero USFDA warnings letters since the inception to any of the company\\u2019s facility. Gland has\\nhigh EBIT margins of ~36% and Asset turns of 2x culminating into healthy \", mdx(\"em\", {\n    parentName: \"p\"\n  }, \"RoIC of ~34%\"), \" which\\nstands best in the industry.\"), mdx(\"h2\", {\n    \"id\": \"span-stylecolororange-font-size1emmental-models-hypothesisspan\"\n  }, mdx(\"span\", {\n    style: {\n      \"color\": \"orange\",\n      \"fontSize\": \"1em\"\n    }\n  }, \"Mental Models Hypothesis\")), mdx(\"h2\", {\n    \"id\": \"huge-growth-opportunity-in-the-us-injectable-market\"\n  }, \"Huge growth opportunity in the US Injectable Market\"), mdx(\"p\", null, \"The United States injectable market is estimated to reach US$ 489 bn valuation by 2025 and\\ngrow at ~15.3% CAGR from 2020 to 2025, faster than other segments. The value of injectables\\nmolecules which may lose patent protection during 2020-2025 stands ~US$67.7 bn, double the\\nvalue of the last 5 years. In the US, the injectables market is fairly concentrated with a few\\ntherapies (including small molecules) forming approximately 80% of the market by value.\\nRegistering a growth of ~38% CAGR from 2014 to 2019, Gland Pharma Ltd. is the fastest growing\\nsmall-molecule generic injectables company in the US market. We expect the US revenue to grow\\nat 20.5% CAGR over the period FY22-FY23E.\"), mdx(\"h3\", {\n    \"id\": \"portfolio-of-complex-products-supported-by-rd-and-regulatory-capabilities\"\n  }, \"Portfolio of complex products supported by R&D and regulatory capabilities\"), mdx(\"p\", null, \"Gland has established internal capabilities in developing complex injectables such as lyophilized\\nproducts, high-potent drugs, and long-acting suspensions. Extensive portfolio comprises major\\ndrugs like Huminsulin (USD$ 2.1 bn), Heparin Sodium (USD$ 2.0 bn), Daptomycin (USD$ 4.5\\nbn), Vanomycin (USD$ 3.1 bn), among others. Gland\\u2019s new launches add ~10%-12% growth for\\nthe company every year and outpace the revenue growth of peers. Gland along with partners had\\n282 ANDA filings in the United States, of which 226 were approved and 56 pending approval.\"), mdx(\"h3\", {\n    \"id\": \"integrated-manufacturing-capabilities-with-a-consistent-compliance-track-record\"\n  }, \"Integrated manufacturing capabilities with a consistent compliance track record\"), mdx(\"p\", null, \"Gland has seven manufacturing facilities comprising two sterile injectables facilities, one\\ndedicated Penems facility, one oncology facility, and three API facilities. The 3 API facilities\\nprovide in-house manufacturing capabilities for critical APIs enabling the company to control costs\\nand quality while mitigating supply chain related risks around key products. Gland\\u2019s scalable\\nmanufacturing capacities, unequivocal focus on product quality, and ability to provide reliable\\nproduct supply at competitive rates have helped it capture high market share in high volume\\nproducts across different dosage/delivery systems. The facility audit is conducted by Marketer\\ncompanies partners that has helped the company to handle compliance in a better way that results\\nin no USFDA warnings letters since the inception of each facility.\"), mdx(\"h3\", {\n    \"id\": \"superior-return-ratios-roic-over-the-peers\"\n  }, \"Superior return ratios (ROIC) over the peers\"), mdx(\"p\", null, \"Gland has high EBIT margins ~36% and Asset turns (2x) that reflects into health retorn ratios,\\nRoIC ~34% which is best in the industry. The company generates Rs 600-800 crore of free cash\\nflow per year despite high working capital requirements (172 days). Gland\\u2019s asset turn range of\\n2.0x-2.3x stands higher than the peers in the industry.\"), mdx(\"h3\", {\n    \"id\": \"global-injectable-market-one-of-the-largest-and-fastest-growing-segment\"\n  }, \"Global Injectable Market: One of the Largest and Fastest Growing Segment\"), mdx(\"p\", null, \"The global injectable market, estimated to be US$432 billion in 2019, grew at ~10.1% CAGR from 2014 to 2019. The injectable is the second largest\\nform of drug delivery and it has grown faster than the global pharma market. Its market share by value has increased from 32% in 2014 to 39% in\\n2019. Faster-than-average growth has been primarily driven by:\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Immediate onset of action and higher bioavailability compared to other forms\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"A unique capability of giving the administrator control over drug delivery to a specific location in a measured manner\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Development of self-injection devices like pen-injectors and auto-injectors improving the convenience of administration for patients\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Growth of Biologics\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Increase in the number of new drug formulations that are not very water-soluble and/or have very low permeability to allow for their adequate absorption from the gastrointestinal tract following oral administration.\")), mdx(\"blockquote\", null, mdx(\"p\", {\n    parentName: \"blockquote\"\n  }, \"Diversified B2B-led Model Across Markets Complemented by B2C Model in India\")), mdx(\"p\", null, \"Gland Pharma is one of the fastest-growing generic injectables-focused companies in the US market. It has established a successful track record of\\noperating the B2B model with leading companies. Leveraging its brand strength and sales network, Gland has successfully established the B2C\\nmodel in India which complements its B2B model overseas. It operates in 60+ countries, including the United States, Europe, Canada, Australia,\\nIndia, and the rest of the world.\\nUS filings update: As of December 31, 2020, Gland along with partners had 282 ANDA filings in the United States, of which 226 were approved and\\n56 pending approval.\"), mdx(\"p\", null, mdx(\"span\", {\n    parentName: \"p\",\n    \"className\": \"gatsby-resp-image-wrapper\",\n    \"style\": {\n      \"position\": \"relative\",\n      \"display\": \"block\",\n      \"marginLeft\": \"auto\",\n      \"marginRight\": \"auto\",\n      \"maxWidth\": \"591px\"\n    }\n  }, \"\\n      \", mdx(\"span\", {\n    parentName: \"span\",\n    \"className\": \"gatsby-resp-image-background-image\",\n    \"style\": {\n      \"paddingBottom\": \"53.63790186125211%\",\n      \"position\": \"relative\",\n      \"bottom\": \"0\",\n      \"left\": \"0\",\n      \"backgroundImage\": \"url('data:image/png;base64,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')\",\n      \"backgroundSize\": \"cover\",\n      \"display\": \"block\"\n    }\n  }), \"\\n  \", mdx(\"picture\", {\n    parentName: \"span\"\n  }, \"\\n          \", mdx(\"source\", {\n    parentName: \"picture\",\n    \"srcSet\": [\"/static/a3f16ea7691bd1298acfaae27480c9cb/dc7b0/Screenshot.webp 591w\"],\n    \"sizes\": \"(max-width: 591px) 100vw, 591px\",\n    \"type\": \"image/webp\"\n  }), \"\\n          \", mdx(\"source\", {\n    parentName: \"picture\",\n    \"srcSet\": [\"/static/a3f16ea7691bd1298acfaae27480c9cb/054b3/Screenshot.png 591w\"],\n    \"sizes\": \"(max-width: 591px) 100vw, 591px\",\n    \"type\": \"image/png\"\n  }), \"\\n          \", mdx(\"img\", {\n    parentName: \"picture\",\n    \"className\": \"gatsby-resp-image-image\",\n    \"src\": \"/static/a3f16ea7691bd1298acfaae27480c9cb/054b3/Screenshot.png\",\n    \"alt\": \"PieChart\",\n    \"title\": \"PieChart\",\n    \"loading\": \"lazy\",\n    \"style\": {\n      \"width\": \"100%\",\n      \"height\": \"100%\",\n      \"margin\": \"0\",\n      \"verticalAlign\": \"middle\",\n      \"position\": \"absolute\",\n      \"top\": \"0\",\n      \"left\": \"0\"\n    }\n  }), \"\\n        \"), \"\\n    \")), mdx(\"h3\", {\n    \"id\": \"extensive-product-portfolio-supported-by-internal-rd-and-regulatory-capabilities\"\n  }, \"Extensive product portfolio supported by internal R&D and regulatory capabilities\"), mdx(\"p\", null, \"Based on strong R&D, Gland has created capabilities in the synthesis of low molecular weight injectables drugs, steroids and oncology drugs, and\\ndeveloping complex injectables such as lyophilized products, high-potent drugs, and long-acting suspensions. In small molecules, Gland has reported\\na CAGR of 38% in the last 5 years. Gland\\u2019 presence in large size molecules (given in the below table) will drive growth over a longer period. Further,\\nnew launches add almost 10%-12% growth for the company every year.\"), mdx(\"h3\", {\n    \"id\": \"extensive-and-vertically-integrated-manufacturing-capabilities-with-consistent-compliance-track-record\"\n  }, \"Extensive and Vertically Integrated Manufacturing Capabilities With Consistent Compliance Track Record:\"), mdx(\"p\", null, \"Gland has seven manufacturing facilities including two sterile injectables facilities, one dedicated Penems facility one oncology facility and three API\\nfacilities. The 3 API facilities provide in-house manufacturing capabilities for critical APIs, thereby controlling costs and quality and mitigating supply\\nchain-related risks around key products. These facilities could manufacture 76.7 crore units for finished formulation and 11,000 kg of APIs per year.\\nGland\\u2019s manufacturing capacities provides strong scale benefits and its strong focus on quality and ability to provide reliable supplies to partners at\\ncompetitive costs has helped the company capture a high market share in high volume products across different dosage/delivery systems. The\\nfacilities audit done by Grand\\u2019 key partners helped the company to handle compliance in a better way that results in no USFDA warnings letters\\nsince the inception of each facility.\"), mdx(\"h3\", {\n    \"id\": \"consistent-compliance-track-record\"\n  }, \"Consistent Compliance Track Record\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"No USFDA warnings letters since the inception of each facility\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Certified as GMP compliant at all manufacturing facilities by the USFDA\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Certain facilities certified by the MHRA (UK), ANVISA (Brazil), AGES (Austria), TGA (Australia) and BGV Hamburg (Germany)\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"35+ audits per year on average, including customer audits and regulatory agency audits\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"GMP certifications for facilities\")), mdx(\"blockquote\", null, mdx(\"p\", {\n    parentName: \"blockquote\"\n  }, \"High entry barriers\")), mdx(\"p\", null, \"According to the IQVIA Report, injectable manufacturers face high entry barriers such as high capital investments, operational costs, manufacturing\\ncomplexities, stricter compliance requirement (because of the sterile nature of products) and high-quality standards resulting in limited competition\\nin the market. Many pharmaceutical companies generally outsource the manufacturing of injectables due to significant costs involved in setting up\\ninjectables facilities, the length of time required for the development and manufacturing of injectables as well as stringent requirements relating to\\nthe quality and safety of injectable products, among other things. Accordingly, Gland Pharma face and will face significant competition from\\npharmaceutical companies that adopt the B2B model and focus on the generic injectables markets such as Recipharm AB, Catalent, Inc., Lonza\\nGroup AG and Piramal Pharma Solutions. In the B2C market, they also compete in India with other injectables manufacturers and distributors. The\\nprimary competitive factors consist of compliance record, price, and size of product portfolio. To stay ahead of its competitors, Gland Pharma regularly\\nupdates existing technology and develops new technology for its manufacturing activities.\"), mdx(\"h3\", {\n    \"id\": \"anti-thesis-pointers\"\n  }, \"Anti Thesis Pointers\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Top-5 products account for 40-45% of Gland\\u2019s US sales, where competition is still limited in Enoxaparin and Caspofungin.\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Discontinuation of export incentives can impact Gland\\u2019s Ebitda margins by ~200bps in the near-term. Gland could offsets this impact,\\nthrough operational cost improvements.\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"Higher USFDA scrutiny on injectables facilities, although frequent customer audits have helped Gland to stay clear of USFDA issues so\\nfar.\")), mdx(\"p\", null, \"/\", mdx(\"em\", {\n    parentName: \"p\"\n  }, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, mdx(\"sub\", null, mdx(\"sup\", null, \"Facts Taken From Axis Securities\"))))))))))))))), \"/\"));\n}\n;\nMDXContent.isMDXComponent = true;","hero":{"full":{"base64":"data:image/jpeg;base64,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","aspectRatio":0.7840531561461794,"src":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/58fe7/hero.jpg","srcSet":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/e0f30/hero.jpg 236w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/86afd/hero.jpg 472w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/58fe7/hero.jpg 944w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/02748/hero.jpg 1416w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/5c241/hero.jpg 1888w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/2e889/hero.jpg 2560w","srcWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/99fbb/hero.webp","srcSetWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/77392/hero.webp 236w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/1f177/hero.webp 472w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/99fbb/hero.webp 944w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/4a492/hero.webp 1416w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/b0b8f/hero.webp 1888w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/22dcf/hero.webp 2560w","sizes":"(max-width: 944px) 100vw, 944px"},"regular":{"base64":"data:image/jpeg;base64,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","aspectRatio":0.7836538461538461,"src":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/1dc0b/hero.jpg","srcSet":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/3a5ce/hero.jpg 163w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/05730/hero.jpg 327w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/1dc0b/hero.jpg 653w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/f72c7/hero.jpg 980w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/6e4a3/hero.jpg 1306w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/2e889/hero.jpg 2560w","srcWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/0acdf/hero.webp","srcSetWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/ac59e/hero.webp 163w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/7660b/hero.webp 327w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/0acdf/hero.webp 653w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/75470/hero.webp 980w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/68d47/hero.webp 1306w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/22dcf/hero.webp 2560w","sizes":"(max-width: 653px) 100vw, 653px"},"narrow":{"base64":"data:image/jpeg;base64,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","aspectRatio":0.7862068965517242,"src":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/eaa58/hero.jpg","srcSet":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/5a3ee/hero.jpg 114w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/41f8f/hero.jpg 229w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/eaa58/hero.jpg 457w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/c309b/hero.jpg 686w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/e3008/hero.jpg 914w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/2e889/hero.jpg 2560w","srcWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/15384/hero.webp","srcSetWebp":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/31fce/hero.webp 114w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/e3e25/hero.webp 229w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/15384/hero.webp 457w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/0258d/hero.webp 686w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/64ea2/hero.webp 914w,\n/static/e3d32bb5170d9ee627ab47ec8bcf9c36/22dcf/hero.webp 2560w","sizes":"(max-width: 457px) 100vw, 457px"},"seo":{"src":"/static/e3d32bb5170d9ee627ab47ec8bcf9c36/0ff54/hero.jpg"}}},"authors":[{"authorsPage":true,"bio":"‚ô•Ô∏è I Love Compounding üë®üèª‚Äçüíª travel ‚úàÔ∏è and a bit of coding.\n","id":"3a286bf3-b37d-5d21-9359-37dad6683a73","name":"Abhishek Jain","featured":true,"social":[{"url":"https://github.com/fiddlytompkus"},{"url":"https://www.linkedin.com/in/abhishek-jain-2033/"}],"slug":"/authors/abhishek-jain","avatar":{"small":{"base64":"data:image/jpeg;base64,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","aspectRatio":1,"src":"/static/d71050ed249229c4e2041a518a0c8ede/fa1ea/abhishek-jain.jpg","srcSet":"/static/d71050ed249229c4e2041a518a0c8ede/afb2b/abhishek-jain.jpg 13w,\n/static/d71050ed249229c4e2041a518a0c8ede/7c20e/abhishek-jain.jpg 25w,\n/static/d71050ed249229c4e2041a518a0c8ede/fa1ea/abhishek-jain.jpg 50w,\n/static/d71050ed249229c4e2041a518a0c8ede/03612/abhishek-jain.jpg 75w,\n/static/d71050ed249229c4e2041a518a0c8ede/61cdf/abhishek-jain.jpg 100w,\n/static/d71050ed249229c4e2041a518a0c8ede/fd013/abhishek-jain.jpg 200w","srcWebp":"/static/d71050ed249229c4e2041a518a0c8ede/e7b2c/abhishek-jain.webp","srcSetWebp":"/static/d71050ed249229c4e2041a518a0c8ede/58718/abhishek-jain.webp 13w,\n/static/d71050ed249229c4e2041a518a0c8ede/74aad/abhishek-jain.webp 25w,\n/static/d71050ed249229c4e2041a518a0c8ede/e7b2c/abhishek-jain.webp 50w,\n/static/d71050ed249229c4e2041a518a0c8ede/ed320/abhishek-jain.webp 75w,\n/static/d71050ed249229c4e2041a518a0c8ede/66016/abhishek-jain.webp 100w,\n/static/d71050ed249229c4e2041a518a0c8ede/6b183/abhishek-jain.webp 200w","sizes":"(max-width: 50px) 100vw, 50px"},"medium":{"base64":"data:image/jpeg;base64,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","aspectRatio":1,"src":"/static/d71050ed249229c4e2041a518a0c8ede/61cdf/abhishek-jain.jpg","srcSet":"/static/d71050ed249229c4e2041a518a0c8ede/7c20e/abhishek-jain.jpg 25w,\n/static/d71050ed249229c4e2041a518a0c8ede/fa1ea/abhishek-jain.jpg 50w,\n/static/d71050ed249229c4e2041a518a0c8ede/61cdf/abhishek-jain.jpg 100w,\n/static/d71050ed249229c4e2041a518a0c8ede/59538/abhishek-jain.jpg 150w,\n/static/d71050ed249229c4e2041a518a0c8ede/fd013/abhishek-jain.jpg 200w","srcWebp":"/static/d71050ed249229c4e2041a518a0c8ede/66016/abhishek-jain.webp","srcSetWebp":"/static/d71050ed249229c4e2041a518a0c8ede/74aad/abhishek-jain.webp 25w,\n/static/d71050ed249229c4e2041a518a0c8ede/e7b2c/abhishek-jain.webp 50w,\n/static/d71050ed249229c4e2041a518a0c8ede/66016/abhishek-jain.webp 100w,\n/static/d71050ed249229c4e2041a518a0c8ede/d9b14/abhishek-jain.webp 150w,\n/static/d71050ed249229c4e2041a518a0c8ede/6b183/abhishek-jain.webp 200w","sizes":"(max-width: 100px) 100vw, 100px"},"large":{"base64":"data:image/jpeg;base64,/9j/2wBDABALDA4MChAODQ4SERATGCgaGBYWGDEjJR0oOjM9PDkzODdASFxOQERXRTc4UG1RV19iZ2hnPk1xeXBkeFxlZ2P/2wBDARESEhgVGC8aGi9jQjhCY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2NjY2P/wgARCAAUABQDASIAAhEBAxEB/8QAFwABAQEBAAAAAAAAAAAAAAAAAAQFA//EABYBAQEBAAAAAAAAAAAAAAAAAAMCAf/aAAwDAQACEAMQAAABvl6ZZpWpHU2ULO6C3//EAB0QAAICAQUAAAAAAAAAAAAAAAIDAAEREhMhIjH/2gAIAQEAAQUCbeAX3C11ljdJbxrbHLGyvlnk/8QAGREAAgMBAAAAAAAAAAAAAAAAABEBECEx/9oACAEDAQE/AVgyeV//xAAXEQEAAwAAAAAAAAAAAAAAAAAAARAR/9oACAECAQE/AWIr/8QAHBAAAgICAwAAAAAAAAAAAAAAAQIAEBEyEiIx/9oACAEBAAY/AieOZllwaCDYztqaLH2Ba//EABsQAQACAwEBAAAAAAAAAAAAAAEAESExUUGB/9oACAEBAAE/IaZTPCXrt1RKxD0Ihec9POzAstc+tQ2GlCcGif/aAAwDAQACAAMAAAAQ88DD/8QAFxEBAQEBAAAAAAAAAAAAAAAAARARIf/aAAgBAwEBPxARqDxP/8QAFxEBAAMAAAAAAAAAAAAAAAAAAREgIf/aAAgBAgEBPxBJyj//xAAdEAEAAgMBAAMAAAAAAAAAAAABESEAMUFRcZHw/9oACAEBAAE/EKMggrVr6xqCkgsT0xTRvzE03ipg/GFitnNpwNm99xsoZZIyRygB4BNZLFXzBNp3G0RoPgz/2Q==","aspectRatio":1,"src":"/static/d71050ed249229c4e2041a518a0c8ede/fd013/abhishek-jain.jpg","srcSet":"/static/d71050ed249229c4e2041a518a0c8ede/a2637/abhishek-jain.jpg 82w,\n/static/d71050ed249229c4e2041a518a0c8ede/15203/abhishek-jain.jpg 164w,\n/static/d71050ed249229c4e2041a518a0c8ede/fd013/abhishek-jain.jpg 200w","srcWebp":"/static/d71050ed249229c4e2041a518a0c8ede/6b183/abhishek-jain.webp","srcSetWebp":"/static/d71050ed249229c4e2041a518a0c8ede/2d087/abhishek-jain.webp 82w,\n/static/d71050ed249229c4e2041a518a0c8ede/29d87/abhishek-jain.webp 164w,\n/static/d71050ed249229c4e2041a518a0c8ede/6b183/abhishek-jain.webp 200w","sizes":"(max-width: 200px) 100vw, 200px"}}}],"basePath":"/","permalink":"https://IntrinsicCompounding.github.io/gland-pharma-a-long-unwinding-ahead/","slug":"/gland-pharma-a-long-unwinding-ahead","id":"919bdb98-fc2d-5224-9df8-4eb6f16cec3b","title":"Gland Pharma - A Long Unwinding Ahead","canonicalUrl":null,"mailchimp":"","next":[]}},"staticQueryHashes":["1143375668","1491088328","1921650733","2068910035","2444214635"]}